uniQure N.V. (NASDAQ:QURE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned an average recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $47.1667.

A number of research firms have recently commented on QURE. HC Wainwright lowered their price target on uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Barclays reissued a “positive” rating on shares of uniQure in a report on Wednesday. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $12.00 to $35.00 in a report on Wednesday, March 11th. Finally, Stifel Nicolaus set a $28.00 price target on uniQure in a report on Tuesday, May 5th.

Insider Activity at uniQure

In other news, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the completion of the transaction, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O’keefe sold 15,936 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $431,228.16. Following the transaction, the insider directly owned 108,864 shares of the company’s stock, valued at $2,945,859.84. This trade represents a 12.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 101,054 shares of company stock worth $2,655,791 in the last three months. Insiders own 4.65% of the company’s stock.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently modified their holdings of the business. Torren Management LLC acquired a new position in uniQure in the 4th quarter worth about $28,000. Jones Financial Companies Lllp increased its holdings in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc acquired a new position in uniQure in the 4th quarter worth about $48,000. Smartleaf Asset Management LLC acquired a new position in uniQure in the 4th quarter worth about $48,000. Finally, CIBC Private Wealth Group LLC acquired a new position in uniQure in the 3rd quarter worth about $50,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure said it plans to submit a BLA for AMT-130 in Huntington’s disease after the FDA indicated the company’s three-year data may support accelerated approval, a major regulatory win that could speed the drug toward market. Article Title
• Positive Sentiment: Analysts turned more constructive after the FDA update, with Cantor Fitzgerald upgrading QURE to overweight and lifting its price target, reinforcing the market’s bullish reaction. Article Title
• Positive Sentiment: Options activity also picked up, with traders buying unusually large volumes of call options, suggesting strong speculative demand tied to the FDA catalyst. Article Title

uniQure Stock Performance

NASDAQ:QURE opened at $48.16 on Thursday. The stock has a fifty day moving average price of $23.55 and a 200-day moving average price of $21.90. The company has a market cap of $3.04 billion, a price-to-earnings ratio of -13.84 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, equities analysts anticipate that uniQure will post -3.64 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.